Thermo Fisher Scientific (TMO) announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). The new registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP. For investors’ note, Thermo Fisher’s August 2021 acquisition of CorEvitas has expanded the company’s Laboratory Products and Biopharma Services segme ...